The writing was on the wall right from the get go. Why do you think no one followed up from the original research done years ago? It wasn't even Nant's IP. I wonder how Nant's patient selection tests performed? Not too well I would suggest.
I am no expert, but oncology is a difficult field and so we may have to consider treatments that target more than one gene if we are to make a success of our work.
BB-501 is still some way off being in the clinic, so where do we go from here?
BLT Price at posting:
14.0¢ Sentiment: None Disclosure: Held
